全文获取类型
收费全文 | 952105篇 |
免费 | 70033篇 |
国内免费 | 3314篇 |
专业分类
耳鼻咽喉 | 13248篇 |
儿科学 | 24535篇 |
妇产科学 | 23495篇 |
基础医学 | 134946篇 |
口腔科学 | 28565篇 |
临床医学 | 83345篇 |
内科学 | 185231篇 |
皮肤病学 | 19424篇 |
神经病学 | 73133篇 |
特种医学 | 37643篇 |
外国民族医学 | 88篇 |
外科学 | 154713篇 |
综合类 | 23454篇 |
现状与发展 | 5篇 |
一般理论 | 234篇 |
预防医学 | 63015篇 |
眼科学 | 21973篇 |
药学 | 75399篇 |
22篇 | |
中国医学 | 3734篇 |
肿瘤学 | 59250篇 |
出版年
2018年 | 9732篇 |
2017年 | 7781篇 |
2016年 | 8488篇 |
2015年 | 9993篇 |
2014年 | 13332篇 |
2013年 | 18860篇 |
2012年 | 26206篇 |
2011年 | 27004篇 |
2010年 | 16262篇 |
2009年 | 15460篇 |
2008年 | 26002篇 |
2007年 | 27175篇 |
2006年 | 27990篇 |
2005年 | 26886篇 |
2004年 | 25696篇 |
2003年 | 24789篇 |
2002年 | 24150篇 |
2001年 | 55542篇 |
2000年 | 57197篇 |
1999年 | 47419篇 |
1998年 | 10596篇 |
1997年 | 9363篇 |
1996年 | 9388篇 |
1995年 | 9142篇 |
1994年 | 8455篇 |
1993年 | 7700篇 |
1992年 | 35607篇 |
1991年 | 34032篇 |
1990年 | 32856篇 |
1989年 | 31949篇 |
1988年 | 29046篇 |
1987年 | 28322篇 |
1986年 | 26326篇 |
1985年 | 25180篇 |
1984年 | 17833篇 |
1983年 | 15130篇 |
1982年 | 7768篇 |
1981年 | 6747篇 |
1979年 | 15758篇 |
1978年 | 10581篇 |
1977年 | 9025篇 |
1976年 | 7859篇 |
1975年 | 8616篇 |
1974年 | 10453篇 |
1973年 | 9849篇 |
1972年 | 9354篇 |
1971年 | 8847篇 |
1970年 | 8414篇 |
1969年 | 7916篇 |
1968年 | 7197篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
1.
目的 探讨集束化干预策略联合闭环管理模式对ICU多重耐药菌感染的防控效果。方法选取2020年1~12月EICU住院患者275例作为对照组,实施常规管理;2021年1~10月EICU住院患者239例作为观察组,在常规管理基础上实施集束化干预策略联合闭环管理。结果实施后,观察组多重耐药菌感染发生率明显低于对照组;患者住院日显著低于对照组,4项护理措施执行率(隔离标识、手卫生、环境消毒、医务人员相关知识知晓)、病原学送检率显著高于对照组(均P<0.05)。结论集束化干预联合信息化闭环管理可有效降低EICU多重耐药菌感染发生率。 相似文献
2.
3.
Given that the global population of elderly individuals is expanding and the difficulty of recovery, hip fractures will be a huge challenge and a critical health issue for all of humanity. Although people have spent more time at home during the coronavirus disease 2019 (COVID-19) pandemic, hip fractures show no sign of abating. Extensive studies have shown that patients with hip fracture and COVID-19 have a multifold increase in mortality compared to those uninfected and a more complex clinical condition. At present, no detailed research has systematically analyzed the relationship between these two conditions and proposed a comprehensive solution. This article aims to systematically review the impact of COVID-19 on hip fracture and provide practical suggestions. We found that hip fracture patients with COVID-19 have higher mortality rates and more complicated clinical outcomes. Indirectly, COVID-19 prevents hip fracture patients from receiving regular medical treatment. With regard to the problems we encounter, we provide clinical recommendations based on existing research evidence and a clinical flowchart for the management of hip fracture patients who are COVID-19 positive. Our study will help clinicians adequately prepare in advance when dealing with such patients and optimize treatment decisions. 相似文献
4.
5.
Malou A.H. Nuijten Thijs M.H. Eijsvogels Valerie M. Monpellier Ignace M.C. Janssen Eric J. Hazebroek Maria T.E. Hopman 《Obesity reviews》2022,23(1):e13370
Postbariatric loss of muscle tissue could negatively affect long-term health due to its role in various bodily processes, such as metabolism and functional capacity. This meta-analysis aimed to unravel time-dependent changes in the magnitude and progress of lean body mass (LBM), fat-free mass (FFM), and skeletal muscle mass (SMM) loss following bariatric surgery. A systematic literature search was conducted in Pubmed, Embase, and Web of Science. Fifty-nine studies assessed LBM (n = 37), FFM (n = 20), or SMM (n = 3) preoperatively and ≥1 time points postsurgery. Random-effects meta-analyses were performed to determine pooled loss per outcome parameter and follow-up time point. At 12-month postsurgery, pooled LBM loss was ?8.13 kg [95%CI ?9.01; ?7.26]. FFM loss and SMM loss were ?8.23 kg [95%CI ?10.74; ?5.73] and ?3.18 kg [95%CI ?5.64; ?0.71], respectively. About 55% of 12-month LBM loss occurred within 3-month postsurgery, followed by a more gradual decrease up to 12 months. Similar patterns were seen for FFM and SMM. In conclusion, >8 kg of LBM and FFM loss was observed within 1-year postsurgery. LBM, FFM, and SMM were predominantly lost within 3-month postsurgery, highlighting that interventions to mitigate such losses should be implemented perioperatively. 相似文献
6.
S. Harrogate J. Barnes K. Thomas A. Isted G. Kunst S. Gupta S. Rudd T. Banerjee R. Hinchliffe R. Mouton 《Anaesthesia》2023,78(11):1393-1408
Tobacco smoking is associated with a substantially increased risk of postoperative complications. The peri-operative period offers a unique opportunity to support patients to stop tobacco smoking, avoid complications and improve long-term health. This systematic review provides an up-to-date summary of the evidence for tobacco cessation interventions in surgical patients. We conducted a systematic search of randomised controlled trials of tobacco cessation interventions in the peri-operative period. Quantitative synthesis of the abstinence outcomes data was by random-effects meta-analysis. The primary outcome of the meta-analysis was abstinence at the time of surgery, and the secondary outcome was abstinence at 12 months. Thirty-eight studies are included in the review (7310 randomised participants) and 26 studies are included in the meta-analysis (5969 randomised participants). Studies were pooled for subgroup analysis in two ways: by the timing of intervention delivery within the peri-operative period and by the intensity of the intervention protocol. We judged the quality of evidence as moderate, reflecting the degree of heterogeneity and the high risk of bias. Overall, peri-operative tobacco cessation interventions increased successful abstinence both at the time of surgery, risk ratio (95%CI) 1.48 (1.20–1.83), number needed to treat 7; and 12 months after surgery, risk ratio (95%CI) 1.62 (1.29–2.03), number needed to treat 9. More work is needed to inform the design and optimal delivery of interventions that are acceptable to patients and that can be incorporated into contemporary elective and urgent surgical pathways. Future trials should use standardised outcome measures. 相似文献
7.
目的探讨放疗干预对宫颈癌荷瘤小鼠的抑瘤作用及其对辅助性T细胞1(Th1)/Th2细胞比例的影响。方法建立宫颈癌荷瘤小鼠模型,随机分为荷瘤组和放疗组,每组各10只,另设对照组10只。放疗组进行放疗干预14天,荷瘤组和对照组不治疗。放疗后4、6、8、10、12、14天测量肿瘤体积;末次治疗后,ELISA法测定血清干扰素-γ(IFN-γ)、白介素-2(IL-2)、IL-4、IL-10含量;计算抑瘤率、胸腺指数和脾脏指数;HE染色观察肿瘤组织学变化;TUNEL染色观察肿瘤组织细胞凋亡情况;流式细胞术检测脾脏Th1/Th2细胞比例;RT-qPCR和Western blot检测脾脏T盒子转录因子(T-bet)、GATA结合蛋白3(GABA-3)mRNA和蛋白表达。结果与荷瘤组比较,放疗组小鼠4、6、8、10、12、14天肿瘤体积及瘤质量减小,血清IL-2、IFN-γ升高,IL-4、IL-10降低,胸腺指数、脾脏指数升高,Th1细胞比例、Th1/Th2增加,Th2细胞比例减少,T-bet mRNA和蛋白及T-bet/GATA-3表达升高,GATA-3 mRNA和蛋白表达降低(P<0.05)。HE染色显示,荷瘤组肿瘤细胞数量较多,核大深染,无明显坏死;放疗组肿瘤细胞数量减少,出现大量坏死组织。TUNEL染色显示,荷瘤组TUNEL阳性细胞较少,放疗组TUNEL阳性细胞明显增多。结论放疗对宫颈癌荷瘤小鼠具有明显抑瘤作用,可能是通过调节T-bet/GATA-3表达,促进Th1/Th2分化平衡,增强机体免疫功能发挥作用。 相似文献
8.
Li Dong Mari Nygård Nathalie C. Støer Ole Klungsøyr Bo T. Hansen 《International journal of cancer. Journal international du cancer》2023,153(2):399-406
Human papillomavirus (HPV) vaccine effectiveness may differ between settings. Here we present the first real-world effectiveness study of HPV vaccination on high-grade cervical lesions from Norway, among women who received HPV vaccine outside the routine program. We performed an observational study of all Norwegian women born 1975 to 1996 and retrieved individual data from nationwide registries on HPV vaccination status and incidence of histologically verified high-grade cervical neoplasia during 2006 to 2016. We estimated the incidence rate ratio (IRR) and 95% confidence intervals (CI) for vaccination vs no vaccination by Poisson regression stratified by age at vaccination <20 years and ≥20 years. The cohort consisted of 832 732 women, of which 46 381 (5.6%) received at least one dose of HPV vaccine by the end of 2016. The incidence rate of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) increased with age regardless of vaccination status and was highest at age 25 to 29, at 637/100 000 among unvaccinated women, 487/100 000 among women vaccinated before age 20 and 831/100 000 among women vaccinated at age 20 or older. The adjusted IRR of CIN2+ between vaccinated and unvaccinated women was 0.62 (95% CI: 0.46-0.84) for women vaccinated below age 20, and 1.22 (95% CI: 1.03-1.43) for women vaccinated at age 20 or older. These findings indicate that HPV vaccination among women too old to be eligible for routine HPV vaccination is effective among women who are vaccinated below age 20 but may not have the desired impact among women who are vaccinated at age 20 or older. 相似文献
9.